Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn-out body parts. The potential applications for this process are diverse and address many critical clinical needs such as treating vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
Tissue Regenix is based in York and has an operation in San Antonio, USA.
Tissue Regenix is no longer an R&D play. Its dCELL® technology enables production of ‘like-for-like’ tissue specific, structure-preserving scaffolds that have been validated in multiple clinical settings. Following the US launch of DermaPure®, we expect a series of further product launches over the next two years in Orthopaedic Sports Medicine and heart valve replacement, substantial markets with significant unmet medical need. The company continues to build long term value despite short term monthly cashburn of ~£0.8m. An NPV of 42p is driven by 3 core product areas; the true value of the platform & product streams has still to be elucidated.